Pashman Stein Wins Rehearing Of Nostrum Fee Battle
The New Jersey Appellate Court on Monday ordered a new hearing over Pashman Stein PC's injunction compelling Nostrum Laboratories to pay at least $500,000 in fees for a generic-drug developer in...To view the full article, register now.
Already a subscriber? Click here to view full article